Lesinurad: A significant advancement or just another addition to existing therapies of gout?

Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more pote...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacology & pharmacotherapeutics 2016-10, Vol.7 (4), p.155-158
Main Authors: Gupta, Ajay, Sharma, Pramod, Misra, Arup, Singh, Surjit
Format: Article
Language:English
Subjects:
Clinical trials
Crystals
Cytokines
Development and progression
Diuretics
Drug dosages
Drug therapy
FDA approval
Gout
Kidneys
Lesinurad
Patient outcomes
Regulatory approval
Review
Rheumatism
Rodents
Studies
Tumor necrosis factor-TNF
Uric acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more potent urate-lowering therapies for treating patients inadequately controlled with available drugs. Lesinurad in combination with a xanthine oxidase inhibitor provides an effective mode of therapy in the management of hyperuricemia associated with gout. Lesinurad is a selective uric acid transporter 1 (URAT1) inhibitor. URAT1 is responsible for the majority of uric acid absorption from kidneys to the circulation. Lesinurad was granted marketing approval based on three randomized, double-blind, placebo-controlled; phase III clinical trials. It is devoid of interaction with organic anion transporters (OATs) such as OAT1 and 3, responsible for drug-drug interactions, an undesirable property associated with probenecid. On-going research is more focused on reducing inflammation consequent to deposition of crystals rather than production and excretion of urate. Various targets are being explored, and interleukin-1 beta inhibition seems to be one of the most promising approaches.
ISSN:0976-500X
0976-5018
DOI:10.4103/0976-500X.195897